全文获取类型
收费全文 | 597篇 |
免费 | 45篇 |
学科分类
医药卫生 | 642篇 |
出版年
2023年 | 5篇 |
2022年 | 9篇 |
2021年 | 20篇 |
2020年 | 14篇 |
2019年 | 11篇 |
2018年 | 25篇 |
2017年 | 24篇 |
2016年 | 16篇 |
2015年 | 22篇 |
2014年 | 33篇 |
2013年 | 29篇 |
2012年 | 41篇 |
2011年 | 46篇 |
2010年 | 34篇 |
2009年 | 19篇 |
2008年 | 22篇 |
2007年 | 27篇 |
2006年 | 38篇 |
2005年 | 24篇 |
2004年 | 33篇 |
2003年 | 24篇 |
2002年 | 13篇 |
2001年 | 5篇 |
2000年 | 14篇 |
1999年 | 5篇 |
1998年 | 5篇 |
1996年 | 4篇 |
1995年 | 2篇 |
1992年 | 4篇 |
1991年 | 2篇 |
1990年 | 2篇 |
1989年 | 5篇 |
1988年 | 4篇 |
1987年 | 3篇 |
1986年 | 9篇 |
1985年 | 6篇 |
1984年 | 5篇 |
1983年 | 3篇 |
1980年 | 2篇 |
1979年 | 3篇 |
1977年 | 2篇 |
1976年 | 3篇 |
1975年 | 2篇 |
1973年 | 4篇 |
1972年 | 2篇 |
1968年 | 3篇 |
1967年 | 2篇 |
1908年 | 1篇 |
1903年 | 3篇 |
1871年 | 1篇 |
排序方式: 共有642条查询结果,搜索用时 15 毫秒
11.
Emmert MY Salzberg SP Theusinger OM Rodriguez H Sündermann SH Plass A Starck CT Seifert B Baulig W Hoerstrup SP Jacobs S Grünenfelder J Falk V 《Heart and vessels》2012,27(3):258-264
Severely decreased ejection-fraction is an established risk-factor for worse outcome after cardiac surgery. We compare outcomes of off-pump coronary artery bypass grafting (OPCAB) and on-pump CABG (ONCABG) in patients with severely compromised EF. From 2004 to 2009, 478 patients with a decreased EF ??35% underwent myocardial-revascularization. Patients received either OPCAB (n?=?256) or ONCABG (n?=?222). Propensity score (PS), including 50 preoperative risk-factors, was used to balance characteristics between groups. PS adjusted logistic regression analysis was performed to assess mortality and major adverse cardiac and cerebrovascular events (MACCE). A composite endpoint for major non-cardiac complications such as respiratory failure, renal failure, rethoracotomy was applied. Complete revascularization (CR) was assumed when the number of distal anastomoses was larger than that of diseased vessels. There was no difference for mortality (2.3 vs. 4.1%; PS-adjusted odds ratio (PS-OR)?=?1.05; p?=?0.93) and MACCE (13.7 vs. 17.6%; PS-OR?=?1.22; p?=?0.50) including myocardial-infarction (1.4 vs. 4.9%; PS-OR?=?0.39; p?=?0.26), low cardiac output (2.3 vs. 4.7%; PS-OR?=?0.75; p?=?0.72) and stroke (2.3 vs. 2.7%; PS-OR?=?0.69; p?=?0.66). OPCAB patients presented with a trend to less frequent occurrence of the non-cardiac composite (12.1 vs. 22.1%; PS-OR?=?0.54; p?=?0.059) including renal dysfunction (PAOR?=?0.77; 95% CI 0.31?C1.9; p?=?0.57), bleeding (PAOR?=?0.42; 95% CI 0.14?C1.20; p?=?0.10) and respiratory failure (PAOR?=?0.39; 95% CI 0.05?C3.29; p?=?0.39). The rate of complete revascularization was similar (92.2 vs. 92.8%; PS-OR?=?0.75; p?=?0.50). OPCAB in patients with severely decreased EF is safe and feasible. It may even benefit these patients in regard to non-cardiac complications and does not come at cost of less complete revascularization. 相似文献
12.
13.
14.
Amir Segev Adva S Rubin Hila Abush Gal Richter-Levin Irit Akirav 《Neuropsychopharmacology》2014,39(4):919-933
Most psychiatric disorders are characterized by emotional memory or learning disturbances. Chronic mild stress (CMS) is a common animal model for stress-induced depression. Here we examined whether 3 days of treatment using the CB1/2 receptor agonist WIN55,212-2 could ameliorate the effects of CMS on emotional learning (ie, conditioned avoidance and extinction), long-term potentiation (LTP) in the hippocampal-accumbens pathway, and depression-like symptoms (ie, coping with stress behavior, anhedonia, and weight changes). We also examined whether the ameliorating effects of WIN55,212-2 on behavior and physiology after CMS are mediated by CB1 and glucocorticoid receptors (GRs). Rats were exposed to CMS or handled on days 1–21. The agonist WIN55,212-2 or vehicle were administered on days 19–21 (IP; 0.5 mg/kg) and behavioral and electrophysiological measures were taken on days 23 and 28. The CB1 receptor antagonist AM251 (IP; 0.3 mg/kg) or the GR antagonist RU-38486 (IP; 10 mg/kg) were co-administered with WIN55,212-2. Our results show that CMS significantly modified physiological and behavioral reactions, as observed by the impairment in avoidance extinction and LTP in the hippocampal-accumbens pathway, and the alterations in depression-like symptoms, such as coping with stress behavior, weight gain, and sucrose consumption. The most significant effect observed in this study was that 3 days of WIN55,212-2 administration prevented the CMS-induced alterations in emotional memory (ie, extinction) and plasticity. This effect was mediated by CB1 receptors as the CB1 receptor antagonist AM251 prevented the ameliorating effects of WIN55,212-2 on extinction and LTP. The GR antagonist RU-38486 also prevented the CMS-induced alterations in extinction and plasticity, and when co-administered with WIN55,212-2, the preventive effects after CMS were maintained. The findings suggest that enhancing cannabinoid signaling could represent a novel approach to the treatment of cognitive deficits that accompany stress-related depression. 相似文献
15.
Christiane Drechsler Benjamin Schmiedeke Markus Niemann Daniel Schmiedeke Johannes Krämer Irina Turkin Katja Blouin Andrea Emmert Stefan Pilz Barbara Obermayer-Pietsch Frank Weidemann Frank Breunig Christoph Wanner 《Journal of inherited metabolic disease》2014,37(2):289-295
Patients with Fabry disease frequently develop left ventricular (LV) hypertrophy and renal fibrosis. Due to heat intolerance and an inability to sweat, patients tend to avoid exposure to sunlight. We hypothesized that subsequent vitamin D deficiency may contribute to Fabry cardiomyopathy. This study investigated the vitamin D status and its association with LV mass and adverse clinical symptoms in patients with Fabry disease. 25-hydroxyvitamin D (25[OH]D) was measured in 111 patients who were genetically proven to have Fabry disease. LV mass and cardiomyopathy were assessed by magnetic resonance imaging and echocardiography. In cross-sectional analyses, associations with adverse clinical outcomes were determined by linear and binary logistic regression analyses, respectively, and were adjusted for age, sex, BMI and season. Patients had a mean age of 40?±?13 years (42 % males), and a mean 25(OH)D of 23.5?±?11.4 ng/ml. Those with overt vitamin D deficiency (25[OH]D?≤?15 ng/ml) had an adjusted six fold higher risk of cardiomyopathy, compared to those with sufficient 25(OH)D levels >30 ng/ml (p?=?0.04). The mean LV mass was distinctively different with 170?±?75 g in deficient, 154?±?60 g in moderately deficient and 128?±?58 g in vitamin D sufficient patients (p?=?0.01). With increasing severity of vitamin D deficiency, the median levels of proteinuria increased, as well as the prevalences of depression, edema, cornea verticillata and the need for medical pain therapy. In conclusion, vitamin D deficiency was strongly associated with cardiomyopathy and adverse clinical symptoms in patients with Fabry disease. Whether vitamin D supplementation improves complications of Fabry disease, requires a randomized controlled trial. 相似文献
16.
17.
Abstract Desialylation of platelets results in platelet clearance by the Ashwell-Morrell Receptors (AMR) found on hepatocytes. Studies suggest that oseltamivir phosphate inhibits human sialidases, enzymes responsible for desialylation, extending the lifespan of circulating platelets. We thus evaluated, the effects of oseltamivir on platelet count (PC) following treatment. Of the 385 patients evaluated for influenza, 283 (73.5%) were influenza-infected. Of the 283 infected patients, 241 (85.2%) received oseltamivir (I + O+) while 42 patients did not (I + O-). One hundred two non-infected patients received oseltamivir (I-O+). The two groups receiving oseltamivir (I + O+, I-O+), demonstrated a statistically greater increase in the PC (57.53 ± 93.81, p = .013 and 50.79 ± 70.59, p = .023, respectively) relative to the group that did not (18.45 ± 89.33 × 109/L). The observed increase in PC was statistically similar (p = .61) in both groups receiving oseltamivir (I + O+, I-O+), suggesting that this effect is independent of influenza. Comparing clinical characteristics between responders and non-responders to oseltamivir treatment showed that only duration of oseltamivir treatment (AOR = 1.30, 95% CI 1.05–1.61, p = .015) was associated with a positive PC response. Our findings suggest a correlation between oseltamivir treatment and an increase in PCs. Future studies assessing the possible uses of oseltamivir in medical conditions characterized by diminished or defective thrombopoiesis are warranted. 相似文献
18.
Hila Emmert Melina Fonfara Elke Rodriguez Stephan Weidinger 《Experimental dermatology》2020,29(8):749-758
Emerging evidence suggests oxidative stress plays a role in the pathophysiology of both atopic dermatitis (AD) and psoriasis (PSO). We established in vitro models of AD and PSO skin, and characterized these models in regard to their oxidative stress state. Both AD and PSO model keratinocytes exhibited elevated reactive oxygen species (ROS) levels and accumulated more DNA damage than control cells after oxidative stress induced by 250 µmol/L H2O2. Elevated ROS levels and DNA damage accumulation could be inhibited by the NADPH oxidase (NOX) inhibitor diphenyleneiodonium (DPI). Further, immunofluorescence analysis revealed the presence of both NOX1 and NOX4 in keratinocytes. By inhibiting NOX1, stress-related signalling cascades and elevated ROS levels could be abrogated, and survival of AD and PSO cells improved. Taken together, this study reveals that inhibition of NOX inhibition could abrogate elevated oxidative stress in a 2D model of AD and PSO. 相似文献
19.
Zschoche Marco Emmert Steffen von Bubnoff Nikolas Ranjbar Mahdy Grisanti Salvatore Heindl Ludwig M. Fend Falko Adamietz Irenäus A. Kakkassery Vinodh 《Der Onkologe》2020,26(11):1056-1064
Die Onkologie - Das okuläre Lymphom wird anhand seiner anatomischen Lokalisation in die intraokulären und periokulären Lymphome eingeteilt. Intraokulär kann die Uvea mit ihren... 相似文献
20.
Kelsie Bogyo Natalie Vena Halie May Hila Milo Rasouly Maddalena Marasa Simone Sanna-Cherchi Krzysztof Kiryluk Jordan Nestor Ali Gharavi 《American journal of medical genetics. Part C, Seminars in medical genetics》2022,190(3):289-301
Studies have shown that as many as 1 in 10 adults with chronic kidney disease has a monogenic form of disease. However, genetic services in adult nephrology are limited. An adult Kidney Genetics Clinic was established within the nephrology division at a large urban academic medical center to increase access to genetic services and testing in adults with kidney disease. Between June 2019 and December 2021, a total of 363 patients were referred to the adult Kidney Genetics Clinic. Of those who completed genetic testing, a positive diagnostic finding was identified in 27.1%, a candidate diagnostic finding was identified in 6.7% of patients, and a nondiagnostic positive finding was identified in an additional 8.6% of patients, resulting in an overall yield of 42.4% for clinically relevant genetic findings in tested patients. A genetic diagnosis had implications for medical management, family member testing, and eligibility for clinical trials. With the utilization of telemedicine, genetic services reached a diverse geographic and patient population. Genetic education efforts were integral to the clinic's success, as they increased visibility and helped providers identify appropriate referrals. Ongoing access to genomic services will remain a fundamental component of patient care in adults with kidney disease. 相似文献